Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

D0422

Sigma-Aldrich

DMEM - high glucose

With sodium bicarbonate, without ʟ-methionine, ʟ-cystine and ʟ-glutamine, liquid, sterile-filtered, suitable for cell culture

Synonym(s):

DME, Dulbecco′s Modified Eagle′s Medium - high glucose, DMEM

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352207
NACRES:
NA.75

product name

Dulbecco′s Modified Eagle′s Medium - high glucose, With 4500 mg/L glucose and sodium bicarbonate, without L-methionine, L-cystine and L-glutamine, liquid, sterile-filtered, suitable for cell culture

Quality Level

400

sterility

sterile-filtered

form

liquid

technique(s)

cell culture | mammalian: suitable

impurities

endotoxin, tested

components

glucose: high
phenol red: yes
L-glutamine: no
sodium pyruvate: yes

shipped in

ambient

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Application

Dulbecco′s Modified Eagle′s Medium (DMEM) is a modification of Basal Medium Eagle (BME) that contains four-fold concentrations of the amino acids and vitamins. The original formulation contained 1000 mg/L of glucose and was used to culture embryonic mouse cells. Since then, it has been modified in several ways to support primary cultures of mouse and chicken cells, as well as a variety of normal and transformed cells. Each of these media offers a different combination of L-glutamine and sodium pyruvate. Additionally, the glucose levels have been raised to 4500 mg/L, contributing to the name "DMEM/High".

Reconstitution

Supplement with 0.584 g/L L-glutamine.

also commonly purchased with this product

Product No.
Description
Pricing

supplement

Product No.
Description
Pricing

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317

Hazard Classifications

Skin Sens. 1

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ruth I C Glasgow et al.
Neurogenetics, 18(4), 227-235 (2017-10-28)
Mitochondrial diseases are characterised by clinical, molecular and functional heterogeneity, reflecting their bi-genomic control. The nuclear gene GFM2 encodes mtEFG2, a protein with an essential role during the termination stage of mitochondrial translation. We present here two unrelated patients harbouring
Stacey L Borrego et al.
Journal of lipid research, 62, 100056-100056 (2021-03-02)
Methionine (Met) is an essential amino acid and critical precursor to the cellular methyl donor S-adenosylmethionine. Unlike nontransformed cells, cancer cells have a unique metabolic requirement for Met and are unable to proliferate in growth media where Met is replaced
Yun Yeon Park et al.
Experimental & molecular medicine, 50(4), 46-46 (2018-04-28)
ATP depletion inhibits cell cycle progression, especially during the G1 phase and the G2 to M transition. However, the effect of ATP depletion on mitotic progression remains unclear. We observed that the reduction of ATP after prometaphase by simultaneous treatment
Mohammad Al Sorkhy et al.
Cell cycle (Georgetown, Tex.), 15(1), 128-136 (2016-01-16)
Families of cyclin-like proteins have emerged that bind and activate cyclin dependent kinases (Cdk)s, directing the phosphorylation of noncanonical Cdk substrates. One of these proteins, Spy1, has demonstrated the unique ability to directly bind and activate both Cdk1 and Cdk2
K Parzych et al.
Cell death & disease, 6, e2031-e2031 (2016-01-01)
The cellular mechanisms that control protein degradation may constitute a non-oncogenic cancer cell vulnerability and, therefore, a therapeutic target. Although this proposition is supported by the clinical success of proteasome inhibitors in some malignancies, most cancers are resistant to proteasome
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service